1. Medicines
  2. Respiratory and Inflammation
  3. ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)
  4. Tracking data for patients with respiratory conditions

Prescribing information

 

Tracking data for patients with respiratory conditions

       

The sensor* for the ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) device provides real data to support your therapeutic decisions

Only available in combination with the ENERZAIR BREEZHALER device.

 

Image showing sensor with ticks for inhalation confirmation and medication reminders

 

To learn how to use the sensor and Propeller® mobile app with the ENERZAIR BREEZHALER device, click here.

Benefits of the sensor* for the ENERZAIR BREEZHALER device

  • Inhalation confirmation for patients3
 

  • Patients can access real data with the option to share with their healthcare professionals to support therapeutic decisions3
 

  • Reminders to support enhanced adherence to medication3
 

The sensor* for the ENERZAIR BREEZHALER device is easily accessible 

 

  • Available through a simple prescription2
    • The first prescription for ENERZAIR® BREEZHALER® should be written to include a sensor. The sensor battery will last for one year from the day of activation. Repeat prescriptions of ENERZAIR®
      BREEZHALER® during this time will not require a sensor. The mobile app will remind your patient when they should ask you for a new sensor prescription.2
 

  • The patient attaches the sensor* to the ENERZAIR BREEZHALER device2
 

  • The patient accesses a personalised profile and owns their personal data3
 

*The Propeller® sensor for the BREEZHALER device (herein referred to as 'the sensor/the sensor for the BREEZHALER device') and the Propeller® mobile app are property of Propeller Health®.

Indication: ENERZAIR BREEZHALER is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.2

ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist.

References

  1. Propeller Health®, QR Rationale for EU Classification-2017-B 2019-07-24 Update.
  2. ENERZAIR BREEZHALER Summary of Product Characteristics.
  3. The Propellor Sensor for ENERZAIR® BREEZHALER® Quick Start Guide, UG-NSPK_en-US_1.3.000NT 2020-02-17.
ENE20-C006 November 2020.
Respiratory and Inflammation
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]